Extracellular matrix differences in glioblastoma patients with different prognoses

Area of Science:

• Neuro-oncology
• Cancer Biology
• Molecular Pathology

Background:

• Glioblastoma (GBM) is the most prevalent malignant brain tumor with poor patient outcomes.
• Tumor recurrence is driven by glioma cell invasion into the surrounding brain tissue.
• Extracellular matrix (ECM) alterations are implicated in glioma invasion and progression.

Purpose of the Study:

• To investigate differences in ECM composition between GBM tumors with distinct prognoses.
• To identify specific ECM molecules associated with patient survival and invasion.
• To evaluate the utility of the ECM invasion spectrum as a prognostic biomarker.

Main Methods:

• Quantitative analysis of mRNA and protein expression for 16 invasion-associated ECM molecules.
• Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) for mRNA levels.
• Immunohistochemistry for protein expression analysis.
• Clinical data analysis including age and Karnofsky performance score.

Main Results:

• Age and postoperative Karnofsky performance score correlated with patient survival.
• Significant differences in mRNA levels of FLT4/VEGFR3, MDM2, and MMP2 between prognostic groups.
• Distinct protein expression of brevican, CD44, RHAMM, integrins (αV, β1), and MDM2.
• The ECM invasion spectrum effectively identified prognostic groups, especially those with poor prognosis.

Conclusions:

• ECM components display differential expression patterns correlating with glioblastoma prognosis.
• The invasion spectrum, derived from ECM expression profiles, serves as a potent prognostic factor for glioblastoma.
• This finding may lead to improved patient stratification and personalized treatment strategies.